Molecular Hydrogen Positively Affects Physical and Respiratory Function in Acute Post-COVID-19 Patients: A New Perspective in Rehabilitation.
Michal Botek, Jakub Krejčí, Michal Valenta, Andrew McKune, Barbora Sládečková, Petr Konečný, Iva Klimešová, Dalibor Pastucha · International journal of environmental research and public health · 2022
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 2019 patients, showed that H₂ therapy, compared with placebo, significantly increased 6 MWT distance by 64 ± 39 m, FVC by 0.19 ± 0.24 L, and, in FEV1, by 0.11 ± 0.28 L (all p ≤ 0.025). These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 2019 patients. Showed that H₂ therapy, compared with placebo, significantly increased 6 MWT distance by 64 ± 39 m, FVC by 0.19 ± 0.24 L, and, in FEV1, by 0.11 ± 0.28 L (all p ≤ 0.025).
What the Researchers Studied
The researchers studied 2019 patients. The study used a randomized, placebo-controlled human clinical trial. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
Reported treatment duration: 14 days. Showed that H₂ therapy, compared with placebo, significantly increased 6 MWT distance by 64 ± 39 m, FVC by 0.19 ± 0.24 L, and, in FEV1, by 0.11 ± 0.28 L (all p ≤ 0.025). The authors concluded that, H₂ inhalation had beneficial health effects in terms of improved physical and respiratory function in acute post-COVID-19 patients. Molecular hydrogen (H₂) is potentially a novel therapeutic gas for acute post-coronavirus disease 2019 (COVID-19) patients because it has antioxidative, anti-inflammatory, anti-apoptosis, and antifatigue properties.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized, placebo-controlled human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 2019 patients. The reported sample size was 19. The study used a randomized, placebo-controlled human clinical trial. The reported treatment duration was 14 days.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.